Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding

A Phase III community-based HIV vaccine trial using the ALVAC-HIV and AIDSVAX B/E prime-boost regimen (RV144) showed a modest vaccine efficacy of 31.2% against HIV acquisition. Participant's understanding of the trial is a key element of its success. This study aimed to understand participant&#...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Khowsroy, Kessuda, Dhitavat, Jittima, Sabmee, Yupa, Laowarakul, Pataramon, Wattanakitwichai, Jutarat, Auetian, Jiraporn, Lothong, Kannika, Boondao, Roongtip, Maythaarttaphong, Sarawan, Yaemwong, Sunee, Excler, Jean-Louis, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc. 2014
Konular:
Clinical Trials/Clinical Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208557/
https://ncbi.nlm.nih.gov/pubmed/24906244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2013.0136
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller